Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
- Sanofi Curbs Supply of Ultra-Fast Acting Insulin Biosimilars in Japan
August 28, 2024
- PNH Drug PiaSky Approved in Europe: Roche/Chugai
August 28, 2024
- Astellas’ Hot Flash Drug Now in Global PIII for Women with Breast Cancer
August 28, 2024
- Guardant Liquid Biopsy Test Approved as CDx for Amivantamab Combo Therapy
August 28, 2024
- A Time for Patience - 4: Toho University Joins Ionis’ Global Trial for FUS-ALS
August 27, 2024
- Mitsubishi Walks Away from Collategene Deal with AnGes
August 26, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- A Time for Patience - 3: As iPSC-Based Drug Discovery Advances, Will 2 Existing Meds Be Repurposed for ALS?
August 26, 2024
- UK OKs Eisai’s Alzheimer’s Drug, but Health Coverage Nixed
August 26, 2024
- Moderna’s JN.1-Tailored COVID Vaccine Approved in Japan
August 26, 2024
- A Time for Patience - 2: Will High-Dose Mecobalamin and Tofersen Become First-Line Treatments in ALS?
August 23, 2024
- Xolair SC Pen Versions Go on Sale in Japan: Novartis
August 23, 2024
- Leqembi Approved in UK: Eisai
August 23, 2024
- Bayer Japan Says No Job Cuts to Soothe Employees’ Nerves as Xarelto Generics Loom
August 23, 2024
- Lilly’s BTK Inhibitor Jaypirca Hits Japan Market for MCL
August 22, 2024
- A Time for Patience - 1: New Drugs for ALS Emerging, Some Close to Approval; Can They Meet Unmet Needs?
August 22, 2024
- Rakuten Medical Japan VP Kodama Promoted to President
August 22, 2024
- Keytruda Regains Top-Selling Status in Japan in April-June: IQVIA
August 21, 2024
- Padcev Approved for Bladder Cancer in China: Astellas
August 21, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…